摘要
目的:评价周剂量多西紫杉醇(泰索帝,DTX)单药治疗晚期老年非小细胞肺癌(NSCLC)的疗效和安全性。方法:46例年龄>70岁的晚期NSCLC患者接受DTX30mg/m2静脉滴注,第1,8,15天,每4周重复。2周期后进行疗效评价。治疗前、治疗后1月及治疗后2月分别用肺癌患者生存质量测定量表FACT-L中文版进行生活质量(QOL)测评。结果:42例可评价的患者,部分缓解5例,稳定14例,进展23例,临床控制率为45.2%。毒副反应轻微,可以耐受。治疗前与治疗后1月、治疗后2月的QOL分值无显著性差异(P>0.05)。结论:周剂量DTX单药治疗老年晚期NSCLC是安全有效的,毒副反应可以接受,不影响生活质量。
Objective：The objective of this study was to evaluate the safety and efficacy of weekly docetaxel monotherapy for elderly patients with advanced non-small cell lung cancer. Methods： Forty-six cases of elderly patients who were over 70 years with advanced NSCLC were treated with docetaxel 30mg/m^2 iv d1, d8, d15. Chemotherapy was repeated every 4 weeks. Patients would be evaluated for response after two cycles of treatment. They were judged by FACT-L（ Chinese version） separately before and after the first ,second month of the treatment. Results： In the 42 patients who were evaluable, 5 cases had partial regression （PR）, 14 cases had no change （ NC ） and 23 cases had progression disease （PD）. The clinical response rate was 45. 2%. The side effects were mild and tolerance. There were no significant differences in the QOL score before the treatment and in the first month, second month after the treatment （P 〉0. 05）. Conclusion： Weekly docetaxel monothrapy in elderly patients with advanced NSCLC are efficacious and feasible. The regimen could be well tolerated and is safe, and does not affect quality of life.
出处
《临床肿瘤学杂志》
CAS
2007年第10期757-758,762,共3页
Chinese Clinical Oncology
